On January 31, 2025, AnaptysBio entered into an Exclusive License Agreement with Vanda Pharmaceuticals Inc. (VNDA), granting Vanda an exclusive, global license for the development and ...

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) and Anaptys AnaptysBio (ANAB) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well. SAN ...

AnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report) has been given an average recommendation of “Moderate Buy” by the ten ratings firms that are presently covering the firm, MarketBeat reports.

Vanda Pharmaceuticals is suing the FDA again, this time alleging the agency is unlawfully delaying a hearing to discuss the rejection of the biotech's stomach disorder drug last year. The FDA has ...

Vanda has previously published an article titled "Potential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2S." In addition to the data published in the article, this poster ...

In a report released today, Derek Archila from Wells Fargo maintained a Buy rating on AnaptysBio (ANAB – Research Report), with a price target of $51.00. The company’s shares closed yesterday ...

WASHINGTON, April 23, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. ("Vanda") (Nasdaq: VNDA) today announced that FDA bureaucrats have committed to delay Vanda's request for a hearing on the ...

WASHINGTON - Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), a biopharmaceutical company with a market capitalization of $252.51 million and impressive gross profit margins of 94.31%, reported that the ...

Get Our Latest Research Report on Vanda Pharmaceuticals Vanda Pharmaceuticals Stock Down 0.5 % VNDA stock opened at $4.31 on Friday. The company has a market cap of $251.34 million, a PE ratio of ...

Vanda trades at a discount despite strong revenue and cash exceeding its market cap, with no debt and substantial sales. The company has three approved products: HETLIOZ, FANAPT, and PONVORY, with ...

Currently, the analyst consensus on AnaptysBio is a Strong Buy with an average price target of $43.00.